Journal article

Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer

Gail Petuna Risbridger, Laura Helen Porter, Joe Zhu, David Byrne, Natalie Lister, Arun Azad, Michael Hofman, Ian Vela, Renea A Taylor, Paul Neeson, Phil Darcy, Joseph Trapani

Journal of the Endocrine Society | The Endocrine Society | Published : 2021

Abstract

Abstract Chimeric antigen receptor T (CAR T) cell therapy is an adoptive immunotherapy that has led to new treatments for lymphoma, leukemia, and other blood cancers; however, its efficacy for prostate cancer remains unproven. Here we report pre-clinical evidence of the efficacy of CAR T cell therapy against the Lewis Y antigen (LeY) using patient-derived models of prostate cancer. To assess the expression of LeY on prostate tumours, we performed immunohistochemistry on a cohort of 41 patient-derived xenografts (PDXs). Cytoplasmic and membrane expression were separately assessed and quantified, for each patient. Overall, 61% (25/41) of PDXs were positive for membrane LeY expre..

View full abstract